<DOC>
	<DOCNO>NCT01895946</DOCNO>
	<brief_summary>Comparison Two Formulations AZD5363 Effect Food Pharmacokinetic Exposure , Safety Tolerability</brief_summary>
	<brief_title>Comparison Two Formulations AZD5363 Effect Food Pharmacokinetic Exposure , Safety Tolerability</brief_title>
	<detailed_description>This study design investigate safety , tolerability pharmacokinetics new drug , AZD5363 , patient advance cancer . This study investigate body handle AZD5363 ( ie , quickly body absorbs remove drug ) , comparison capsule tablet formulation effect food AZD5363 tablet formulation .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Aged least 18 year The presence solid , malignant tumour , exclude lymphoma , resistance standard therapy standard therapy exist The presence least one lesion accurately assess baseline Computerised Tomography ( CT ) , Magnetic Resonance Imaging ( MRI ) plain Xray suitable repeat assessment Estimated life expectancy 12 week Clinically significant abnormality glucose metabolism Spinal cord compression brain metastasis unless asymptomatic , treat stable ( require steroid ) Evidence severe uncontrolled systemic disease , include active bleeding diatheses active infection include hepatitis B , C Human Immunodeficiency Virus ( HIV ) Evidence clinically significant cardiac abnormality , uncontrolled hypotension , leave ventricular ejection fraction lower limit normal site experience significant cardiac interventional procedures A bad reaction AZD5363 drug similar structure class</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Advanced solid malignancy , AZD5363 ,</keyword>
	<keyword>food effect ,</keyword>
	<keyword>formulation comparison</keyword>
</DOC>